# Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma

> **NCT04280848** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 67 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** UCPVax
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04280848
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-26
- **Primary completion:** 2023-12-21
- **Final completion:** 2024-12-31
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04280848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04280848, "Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04280848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*